SCYNEXIS develops antifungal drugs for hard to treat fungal infections, aimed at hospital patients and the physicians who treat them. SCYX reports earnings on Wed, Nov 4, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 13 | Guggenheim | Maintained | Buy |
Seasonality
How SCYX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
Whale Options Flow
90DNo whale options trades in SCYX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SCYX is in one of them and how their past SCYX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SCYX in an article yet. Here's the latest on the wider market.
About Scynexis
SCYNEXIS is a pharmaceutical company based in Jersey City, New Jersey, that develops antifungal medicines. Its approved product, BREXAFEMME, treats vaginal yeast infections, and it has been licensed to GSK. Its main development candidate, SCY-247, is an oral and intravenous antifungal being studied for serious fungal infections, mainly in hospital patients with weakened immune systems and in other patients at high risk. The company's customers are mainly physicians at major medical centers who treat these patients.
- Headquarters
- Jersey City, NJ